AIGH Capital Management LLC raised its stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 334.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,171,765 shares of the company's stock after purchasing an additional 902,000 shares during the quarter. OrthoPediatrics comprises approximately 2.6% of AIGH Capital Management LLC's holdings, making the stock its 12th biggest holding. AIGH Capital Management LLC owned approximately 4.49% of OrthoPediatrics worth $26,095,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of OrthoPediatrics in the 2nd quarter valued at about $24,347,000. Granahan Investment Management LLC boosted its position in shares of OrthoPediatrics by 35.1% in the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock worth $14,231,000 after buying an additional 232,760 shares during the period. Wasatch Advisors LP boosted its position in shares of OrthoPediatrics by 56.6% in the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company's stock worth $9,865,000 after buying an additional 186,357 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of OrthoPediatrics in the second quarter valued at about $4,636,002. Finally, Roubaix Capital LLC grew its stake in shares of OrthoPediatrics by 23.8% in the first quarter. Roubaix Capital LLC now owns 290,047 shares of the company's stock valued at $4,603,000 after buying an additional 55,724 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.
OrthoPediatrics Stock Performance
NASDAQ:KIDS opened at $32.22 on Friday. OrthoPediatrics Corp. has a one year low of $14.42 and a one year high of $34.53. The company has a current ratio of 4.55, a quick ratio of 2.00 and a debt-to-equity ratio of 0.29. The business's 50-day simple moving average is $23.89 and its 200 day simple moving average is $19.86.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.02). The business had revenue of $72.66 million for the quarter, compared to analyst estimates of $68.50 million. OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. Research analysts forecast that OrthoPediatrics Corp. will post -1.09 earnings per share for the current year.
Insider Buying and Selling at OrthoPediatrics
In other news, Director David R. Pelizzon sold 302,369 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the director directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,100,000 shares of company stock worth $46,747,931 over the last quarter. 32.50% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on KIDS shares. Canaccord Genuity Group boosted their price target on OrthoPediatrics from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Wednesday, October 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OrthoPediatrics in a research report on Tuesday. TD Cowen lifted their price objective on shares of OrthoPediatrics from $23.00 to $28.00 and gave the company a "buy" rating in a research note on Wednesday, October 28th. Needham & Company LLC reiterated a "buy" rating and set a $35.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, October 28th. Finally, BTIG Research boosted their target price on shares of OrthoPediatrics from $29.00 to $30.00 and gave the stock a "buy" rating in a research report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, OrthoPediatrics presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.75.
Get Our Latest Stock Report on KIDS
About OrthoPediatrics
(
Free Report)
OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.
Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.